NCT02184819View on ClinicalTrials.gov

Preoperative Levosimendan in CABG Patients With Poor LV Function

PHASE3CompletedINTERVENTIONAL
Enrollment

335

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

November 30, 2015

Conditions
Coronary Artery Bypass GraftingLeft Ventricular Dysfonction
Interventions
DRUG

levosimendan

24 hour continuous infusion at the rate of 0,1 µg/kg/min

DRUG

Placebo

24 hour infusion at a rate of 0,1 µg/kg/min assuming that it contains study drug

Trial Locations (1)

75015

Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, France, Paris

All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02184819 - Preoperative Levosimendan in CABG Patients With Poor LV Function | Biotech Hunter | Biotech Hunter